|
|
Volumn 351, Issue 9119, 1998, Pages 1829-1830
|
|
What lessons can be learnt from withdrawal of mibefradil from the market?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMIODARONE;
ASTEMIZOLE;
BEPRIDIL;
CISAPRIDE;
CYCLOPHOSPHAMIDE;
CYCLOSPORIN;
DESIPRAMINE;
ERYTHROMYCIN;
ETOPOSIDE;
FLECAINIDE;
FLUTAMIDE;
HALOFANTRINE;
IFOSFAMIDE;
IMIPRAMINE;
MEVINOLIN;
MEXILETINE;
MIBEFRADIL;
PIMOZIDE;
PROPAFENONE;
QUINIDINE;
SIMVASTATIN;
TACROLIMUS;
TAMOXIFEN;
TERFENADINE;
THIORIDAZINE;
VINBLASTINE;
VINCRISTINE;
DRUG LEGISLATION;
DRUG MARKETING;
HUMAN;
PRIORITY JOURNAL;
SHORT SURVEY;
SIDE EFFECT;
|
|
EID: 0032551211
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/S0140-6736(05)78800-0 Document Type: Note |
|
Times cited : (85)
|
|
References (8)
|
